Skip to main content

Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?

European Journal of Nuclear Medicine and Molecular Imaging volume 42, pages 1949–1954 (2015)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Cherry SR, Sorenson JA, Phelps ME. Physics in nuclear medicine. Elsevier Health Sciences, 2012; p. 73.

  2. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656–63.

    CAS  Article  PubMed  Google Scholar 

  3. Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371(16):1556–7.

    PubMed  Google Scholar 

  4. Zaknun JJ, Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, O’Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013 May;40(5):800–16. doi: 10.1007/s00259-012-2330-6. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):584. O’Dorisiol, T M [corrected to O’Dorisio, T M].

  5. Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T, Di Iorio V, D’Errico V, Caroli P, Monti M, Paganelli G. Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC. Eur J Nucl Med Mol Imaging 2015 [Epub ahead of print].

  6. Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging 2014;41(10):1845–51.

    CAS  Article  PubMed  Google Scholar 

  7. Forrer F, Uusijärvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005;46(8):1310–6.

    CAS  PubMed  Google Scholar 

  8. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2010;51(3):383–90.

    Article  PubMed  Google Scholar 

  9. Sabet A, Haslerud T, Pape UF, Sabet A, Ahmadzadehfar H, Grünwald F, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014;41(2):205–10.

    CAS  Article  PubMed  Google Scholar 

  10. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32(2):148–55.

    Article  PubMed  Google Scholar 

  11. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010;54(1):92–9.

    CAS  PubMed  Google Scholar 

  12. Waitz D, Putzer D, Stevanovic A, Kroiss A, Nilica B, Gradl J, et al. 68Ga-DOTA-TOC PET/CT and 18F-FDG PET in the follow-up of neuroendocrine tumor patients treated by PRRT. Eur J Nucl Med Mol Imaging 2011;38(2, Suppl):S207.

    Google Scholar 

  13. Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, et al. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014;41(2):214–22.

    CAS  Article  PubMed  Google Scholar 

  14. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S–7.

  15. Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30(10):1100–6.

    CAS  Article  PubMed  Google Scholar 

  16. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 2011;38(10):1788–97.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  17. Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging 2014;41(2):223–30.

    CAS  Article  PubMed  Google Scholar 

  18. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13):2124–30.

    CAS  Article  PubMed  Google Scholar 

  19. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50(9):1427–34.

    CAS  Article  PubMed  Google Scholar 

  20. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16(3):978–85.

    CAS  Article  PubMed  Google Scholar 

  21. Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40(6):881–8.

    CAS  Article  PubMed  Google Scholar 

  22. Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging 2013;40(3):364–72.

    CAS  Article  PubMed  Google Scholar 

  23. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514–23.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  24. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 Feb 10;364(6):501–13. doi: 10.1056/NEJMoa1003825. Erratum in: N Engl J Med 2011 Mar 17;364(11):1082.

  25. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26(8):1316–23.

    CAS  Article  PubMed  Google Scholar 

  26. Kesavan M, Claringbold PG, Turner JH. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology 2014;99(2):108–17.

    CAS  Article  PubMed  Google Scholar 

  27. Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks RJ. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging 2010;37(10):1869–75.

    CAS  Article  PubMed  Google Scholar 

  28. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011;29(7):934–43.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  29. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:92S–8.

  30. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29(17):2416–23.

    CAS  Article  PubMed  Google Scholar 

  31. Martini C, Gamper EM, Wintner L, Nilica B, Sperner-Unterweger B, Bernhard H, Virgolini I. Health-related quality of life in patients with gastrointestinal neuroendocrine tumours – a systematic scoping review (submitted).

  32. Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015;42(1):5–19.

    CAS  Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Affiliations

  1. Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria

    Irene Virgolini

Authors
  1. Irene Virgolini
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Innsbruck Team

Corresponding author

Correspondence to Irene Virgolini.

Additional information

This editorial commentary refers to the article http://dx.doi.org/10.1007/s00259-015-3105-7.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Virgolini, I., The Innsbruck Team. Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? . Eur J Nucl Med Mol Imaging 42, 1949–1954 (2015). https://doi.org/10.1007/s00259-015-3153-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-015-3153-z

Keywords

  • Lanreotide
  • Peptide Receptor Radionuclide Therapy
  • Selective Internal Radiation Therapy
  • Orphan Designation
  • Radiolabelled Peptide